tbuckley/cabot-search huggingface dataset:
Proposed staging system modifications for advanced bronchioloalveolar carcinoma supported with a population-based validation study
Authors: J. A. Zell, S. Ou, A. Ziogas, H. Anton-Culver
Journal: Journal of Clinical Oncology (2007)

7559 Background: Concordant with surgical series, our prior analysis of US SEER data demonstrates improved survival for BAC patients with stage IIIB disease due to multiple lesions in the same lobe compared to other stage IIIB patients, and also for patients with ipsilateral multicentric BAC compared to those with distant metastasis. In order for the BAC staging system to accurately reflect survival for these distinct patient subsets, we propose a revised staging system for advanced BAC and validate this system using California Cancer Registry (CCR) data. Methods: A case-only analysis of incident BAC cases in CCR during 1999–2003 was conducted. Based on modeling from our prior SEER analysis, the T4 descriptor for multiple tumors in the same lobe was downstaged to T3, and the M1 descriptor for ipsilateral multicentric BAC was downstaged to T4. The primary outcome measured was overall survival (OS). OS univariate analyses were conducted using the Kaplan-Meier method; multivariate survival analyses were performed using Cox proportional hazards ratios. Results: 1909 incident cases of histologically-confirmed BAC were analyzed. Using the proposed criteria, 162 (25%) of the 654 advanced BAC cases were reclassified: 73 cases with multiple lesions in the same lobe as T3 (stage II T3N0M0 [n=53] or T3NXM0 [n=1], stage IIIA T3N1–2M0 [n=18], stage IIIB T3N3M0 [n=1]); 89 cases with ipsilateral intrapulmonary metastasis were reclassified as T4 (stage IIIB, T4N1- 3M0). Univariate OS analysis of this validation set reveals an improved fit for the proposed staging system compared to the existing staging system ( Table 1 ). Analysis by stage reveals improvement in this proposed prognostic model over the existing staging system on multivariate survival analysis after adjustment for relevant clinicopathologic variables ( Table ). Conclusions: Our proposed BAC staging system modifications more accurately reflect survival characteristics for this unique type of non-small-cell lung cancer. [Table: see text]
The Alpha, Beta, Gammas of Oral Human Papillomavirus Infection and Head and Neck Cancer Risk
Authors: Dana E. Rollison, Maura L. Gillison
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
More reasons why Dutch GPs are happier
Authors: Helene J Irvine
Journal: BMJ (2016)

Some additional factors may contribute to British GPs being less happy than their Dutch counterparts (Feature 9 January).1

British patients are more likely to experience social deprivation and sedentary lifestyles, predisposing them to increased rates of obesity, diabetes, and alcohol or substance misuse.2 The legacy of poor occupational health and safety standards, in what was a heavily industrialised society, and …
Opiate addiction and suicidal behaviors
Authors: J T Moore, L L Judd, W W Zung, G R Alexander
Journal: American Journal of Psychiatry (1979)

The authors tested the hypothesis that people addicted to opiates manifest more psychopathology in areas that have been identified as predictors for high risk of suicidal behavior than do normal control subjects. They gave 278 patients in a methadone maintenance program and 207 normal control subjects the index of Potential Suicide (IPS), a scale designed to assess suicidal risk. Using discriminate function analysis, the authors found that 87% of 100 of the methadone patients and 98% of 100 of the normal control subjects were correctly identified on the basis of the IPS data.
Development and psychometric properties of the Prostate Cancer Radiation Toxicity Questionnaire
Authors: G. Rodrigues, G. Bauman, M. Lock, D. D'Souza, J. Mahon
Journal: Journal of Clinical Oncology (2007)

15631 Background: The objective of this study was to construct a prostate cancer late radiation toxicity (PCRT) questionnaire with associated health-related quality of life (HRQoL) domains. Methods: A literature review of prostate cancer toxicity scales and HRQoL instruments generated a list of potential items for inclusion into the PCRT. An initial questionnaire was subjected to both patient (n=8) and expert (n=7) opinion. A pilot study (n=37) assessed patient feedback, ease of administration, and acceptance. Item reduction (n=100) based on response heterogeneity, factor analysis and Cronbach's alpha analysis was performed. Reliability testing (n=274) was performed using test- retest methodology and calculation of intraclass correlation coefficients (CC). Validity testing (n=274) consisted of discriminant and various construct validity tests (1. calculation of Pearson CC between the PCRT and different HRQoL instruments, and 2. comparison of mean brachytherapy versus external-beam radiation therapy domain scores by Student's t-test). Results: Construction of an initial 29 item (5 point Likert scale) questionnaire with genitourinary, gastrointestinal, and sexual symptom and bother items was performed. The pilot study demonstrated that the PCRT was comprehensive (94%) and easy to administer (1.3% missing data). Item reduction resulted in three HRQoL subscales: (4 item GU alpha = 0.639, 12 item GI = 0.859, 5 item sexual = 0.700). Test-retest reliability demonstrated intraclass correlation coefficients of 0.811 (GU), 0.842 (GI), and 0.740 (sexual). Discriminate validity analysis demonstrated Pearson CC of 0.449 (GU-GI), 0.200 (sexual-GU), and 0.09 (sexual-GI). Content validity analysis demonstrated significant correlations between analogous subscales between PCRT and the PCQoL (range 0.35–0.78). Smaller correlations exist between the PCRT and FACT-G (0.19–0.39) and SF-36 (0.03–0.34). Difference scores between brachytherapy and external-beam favoured brachytherapy [4.13 (GI, p=0.02), 3.50 (sexual, p=0.36), and 3.63 (GU, p=0.14)]. Conclusion: The HRQoL subscales generated from the PCRT have been shown to have good internal consistency with documented reliability and validity. No significant financial relationships to disclose.
Radioautographic Study of Epidermal Cell Proliferation and Migration in Normal and Neoplastic Tissues of Rabbits&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: A. L. Rashad, C. A. Evans
Journal: JNCI Journal of the National Cancer Institute (1968)

The tritiated thymidine (3H-TDR) radioautography technique was used to examine the kinetics of cellular proliferation and migration in skin papillomas of rabbits induced by the virus of Shope (SPV). The mean cell cycle time in the domestic rabbit Shope papilloma was 21.2 hours and the mean durations of S, G2, M, and G1 phases were 5.3, 4.8, 0.3, and 10.8 hours, respectively. The pattern of cell migration in the cottontail Shope papilloma resembled that in the domestic rabbit Shope papilloma. Maximal labeling occurred in the granular layer between 32 and 80 hours in the former and between 60 and 84 hours in the latter tumor. The label could not be detected in the Shope papillomas 1 week after 3H-TDR injection, but it persisted in the dorsal epidermis up to day 14. A comparison of the labeling indices was made between 3 tumors induced by SPV, 3 other tumors induced by the chemical carcinogen 7,12-dimethylbenz[a]anthracene, and the normal epidermis of rabbits. The indices were 4–6 times greater in the viral and chemical tumors than in the normal counterpart, the dorsal epidermis. Similarly at 3 hours after 3H-TDR injection, the tumors showed 4–10 times as many labeled cells in the basal layer as in the dorsal epidermis.
Abstract 18567: Enhancement of Collaterals by Resveratrol in a Rabbit Model of Hind Limb Ischemia
Authors: Eman A El Eter, Hana Al Zamil, Maha Deif
Journal: Circulation (2013)

Background: Resveratrol, a naturally occurring phytoalexin induced cardio angiogenic effects. It is not recognized to induce collaterals in limb ischemia. Methods: Rabbits were assigned into:1) ischemic , 2) ischemic + Resveratrol. (Loading s.c dose 2.5 mg/kg, followed by 2.5 mg/day/orally x 28 days) and 3) ischemic + LY294002 (3-phosphatidyl inositol (PI3) kinase inhibitor) + Resveratrol. Limb ischemia was induced as described [2]. Results/conclusions: Resveratrol produced an increase in limb blood pressure ratio by 40% and angiographic score. Angiogenesis detected by CD31 immunostaining and upregulation of eNOS protein expression. LY294002 , attenuated collaterals and angiogenesis. Conclusions: reveratrol enhanced micro and macrocollateral development in ischemic limbs via Akt/PI3-kinase pathway and eNOS providing a possible therapeutic potential for ischemic limbs. References:[1] Bradamante S, Barenghi L, Villa A. Cardiovasc Drug Rev 2004; 22: 169-188.[2] Takeshita S, Rossow ST, Kearney M, et al. J Clin Invest 1994; 93: 662-670.
Preoperative serum VEGF-A levels to predict survival for Caucasian and Asian patients undergoing resection for gastric adenocarcinoma.
Authors: Do Joong Park, Changhwan Yoon, Geoffrey Yuyat Ku, Daniel G. Coit, Vivian E. Strong, Han-Kwang Yang, Hyung-Ho Kim, Yun-Suhk Suh, Sam S. Yoon
Journal: Journal of Clinical Oncology (2015)

81 Background: Clinical trials in gastric adenocarcinoma (GC) patients of vascular endothelial growth factor A (VEGF-A) targeted therapies have suggested these therapies may be more effective in Caucasians (CA) than in Asians (AS). Methods: Levels of VEGF-A in serum were measured in CA and AS treated at two institutions prior to potentially curative surgical resection for GC, and levels were correlated with overall survival (OS). Results: There were significant differences in CA (n=118) and AS (n=115) in terms of age (median 66 vs. 59), use of neoadjuvant (52% vs. 14%) and adjuvant therapy (27% vs. 18%), tumor location (58% upper/GE junction vs. 80% distal/middle), Lauren classification (57% vs. 46% intestinal), and TNM status (65% stage II or III vs. 55% stage I). CA had a median VEGF-A levels that was 95% higher than that of AS as well as a much higher standard deviation (88.1 + 6206 vs. 45.2 + 76.3 pg/ml, p&lt;0.001). CA with proximal/nondiffuse tumors had significantly higher VEGF-A levels than those with distal/nondiffuse or diffuse tumors (median 120 vs. 71 and 50 pg/ml; p=0.016). The 5-year OS for CA with low vs. high VEGF-A levels was 72.4% vs. 43.4% (p=0.001). In AS, there was no significant difference in 5-year OS according to VEGF-A level (77.4%% vs.85.6%, p=0.236). On multivariate analysis, tumor size, location, grade, N stage, and serum VEGF-A level were independent predictors of OS in CA. Conclusions: In patients with resectable GC, higher circulating VEGF-A levels are independently associated with decreased OS in CA but AS, suggesting varying importance of this angiogenic factor in GC progression among different races.
Cataract extraction with multifocal intraocular lens implantation
Authors: Jonathan C Javitt, Roger F Steinert
Journal: Ophthalmology (2000)

Objective Two million cataract extractions are performed annually in the United States. The procedure is nearly always accompanied by implantation of a monofocal intraocular lens (IOL), which corrects the patient's distance vision. The authors' objective was to measure visual function and quality-of-life outcomes associated with bilateral implantation of a multifocal IOL, which corrects distance and near vision, and to compare the outcomes with those of the standard therapy. Design A prospective, randomized, double-masked, clinical trial was conducted at eight sites in the United States, seven sites in Germany, and one site in Austria. Participants Participants included 245 cataract patients, 127 of whom received the multifocal IOL bilaterally and 118 of whom received a monofocal IOL of nearly identical construction bilaterally. Methods Clinical data included visual acuity (VA), complications, and adverse events. Quality-of-life data were collected using a previously validated survey instrument at baseline, after first eye surgery, and after second eye surgery. Results At 3 months after surgery, patients who had received multifocal IOLs had significantly better uncorrected and distance corrected binocular near VA compared with patients who had received monofocal IOLs (mean uncorrected VA, 20/26 multifocal vs. 20/40 monofocal; mean distance corrected VA, 20/28 multifocal vs. 20/45 monofocal; P < 0.0001). Additionally, 96% of patients who had received multifocal IOLs and 65% of patients who had received monofocal IOLs achieved both 20/40 and J3 (Jaeger) or better uncorrected, binocular distance and near visual acuities (P < 0.0001). Patients who had received multifocal IOLs were more likely than patients who had received monofocal IOLs to never wear glasses overall (32% multifocal vs. 8% monofocal; P < 0.0001). On a 4-point scale, patients who had received multifocal IOLs on average reported having between "a little bit" and "some" glare or halo, whereas patients who had received monofocal IOLs reported between "none" and "a little bit" of glare or halo (1.57 vs. 0.43; P < 0.001). Patients who had received multifocal IOLs rated their vision without glasses better overall at near and at intermediate distances (P ≤ 0.002) and demonstrated better visual function for near tasks and social activities. Conclusions Cataract patients who received multifocal IOLs at time of surgery obtained better uncorrected and distance corrected near VA and reported better overall vision, less limitation in visual function, less spectacle dependency, and more glare or halo than those who received traditional monofocal IOLs.
Clinical depression among narcotic addicts maintained on methadone in the community
Authors: M M Weissman, F Slobetz, B Prusoff, M Mezritz, P Howard
Journal: American Journal of Psychiatry (1976)

In a study of 106 predominantly young, lower-social-class men participating in a methadone maintenance program, the authors found that about one-third were moderately to severely depressed as assessed on standard rating scales of depression. The depressive symptoms were associated with a decrease in social functioning, increase in stress in the past 6 months, and a history of alcohol abuse. Because the combination of depression and drug addiction creates a high risk for suicide, depressive symptoms require early detection and treatment. The authors point to the need for more research on treatment approaches, particularly the use of psychotropic drugs.
Weekly paclitaxel (P) plus carboplatin (C) as salvage therapy in metastatic transitional cell carcinoma (TCC) of the urothelium previously treated with MVAC: Phase II trial
Authors: T. Kouno, M. Ando, K. Yonemori, K. Matsumoto, C. Shimizu, M. Komiyama, E. Okajima, N. Matsuoka, H. Fujimoto, Y. Fujiwara
Journal: Journal of Clinical Oncology (2005)

4719 Background: MVAC has been one of standard chemotherapy regimens for TCC. However, no standard salvage regimen for TCC exists for patients (pts) who failed MVAC. P is active for TCC and C might enhance its efficacy. Higher dose of weekly P (135mg/m2) plus C (AUC2) for TCC was reported to be intolerable (Cancer Invest 22: 374, 2004). In ovarian or lung cancer, weekly P (80mg/m2) plus C (AUC2) is active. Effective and tolerable salvage regimens for TCC are needed. Methods: From May 2003 to November 2004, 25 pts of metastatic TCC with prior MVAC were entered to this study. 12 pts had recieved MVAC as adjuvant or neoadjuvant chemotherapy for invasive carcinoma and 13 pts as chemotherapy for distant metastasis. Platinum-free interval (PFI) was defined as the length from last MVAC to current chemotherapy. Weekly P (80mg/m2) and C (AUC2) were administered on day 1, 8, 15, 22, 29, 36 and repeated every 7 weeks until progression or intolerable toxicity (maximum 18 cycles). Results: Pts’ characteristics were as follows; Median age 68 (53–80), PS 0/1/2/3: 8/13/2/2 pts, visceral metastasis 19 pts (76%) and median PFI 5.3 months (1.5–106). The median number of cycles was 10 (2–18) and 7 pts (29%) withdrew during first six cycles because of toxicities. Among assessable 21 pts, 2 complete and 5 partial responses were observed (overall response rate 33.3%, 95% CI 14.6–57.0%). 11 pts had stable disease and 3 pts had progression. The relations between PFI and tumor response were as follows; < 6 months, 27.3% (3/11) and ≥ 6 months, 40% (4/10), respectively (p=ns). Median progression-free and overall survivals were 3.7 and 7.9 months, respectively. One pt died from sepsis within 1 month from the last cycle of chemotherapy. Grade 3–4 CTC-toxicities were as follows: anemia (30%), thrombocytopenia (0%), neutropenia (54%) and febrile neutropenia (12%). Most common non-hematological toxicities were alopecia (≥Grade1; 75%) and neurotoxicity (Grade1; 58.3%, Grade2; 12.5%, ≥Grade3; 0%). Conclusions: Weekly P plus C was tolerable and active salvage regimen for TCC previously treated with MVAC. No significant financial relationships to disclose.
Endocrine effects of letrozole + triptoreline compared to tamoxifen + triptoreline as adjuvant treatment of premenopausal patients with early breast cancer
Authors: E. Rossi, G. Esposito, F. Di Rella, A. Gravina, G. Landi, F. Nuzzo, C. Pacilio, K. Monaco, M. Piccirillo, A. de Matteis
Journal: Journal of Clinical Oncology (2007)

578 Background: Few data have been reported on endocrine effects of combining LHRH-analogues with aromatase inhibitors (AI) in premenopausal patients. However, promising data in postmenopausal patients make this information interesting in view of extending adjuvant AI to premenopausal patients. We are conducting a phase 3 trial (Hormonal adjuvant treatment bone effects (HOBOE)) comparing tamoxifen (Tam), letrozole (L) and L + zoledronate (Z) for the effect on bone mineral density at 1 year. Postmenopausal and premenopausal patients are eligible, the latter also receiving monthly triptorelin (Tr). Methods: This analysis is limited to 76 premenopausal patients with early endocrine-responsive breast cancer, 28 treated with Tam+Tr and 48 with L+Tr±Z, assuming that Z has no endocrine effects. Serum 17-β-estradiol, FSH, LH, Δ4-androstenedione, testosterone, dehydroepiandrosterone-solphate, progesterone, ACTH and cortisol are measured at baseline and after 6 months of treatment. We compared, for each hormone, 6-month values between treatment groups by applying Exact Wilcoxon-Mann-Whitney test. Results: Baseline values for all the hormones were comparable between treatment groups. At 6 months, statistically significant differences were found for estradiol, FSH, LH and cortisol (see table , with median and range values by treatment group). No differences were found in plasma levels of testosterone, progesterone, ACTH, androstenedione, and dehydroepiandrosterone between the two groups. Conclusions: These data support that letrozole compared to tamoxifen, in combination with triptorelin, induces a more intense estrogen suppression also in premenopausal patients. Such evidence makes reasonable the hypothesis that the higher efficacy of letrozole versus tamoxifen shown in postmenopausal patients could be confirmed also in premenopausal patients. [Table: see text] No significant financial relationships to disclose.
Managing alcoholic liver disease
Authors: Vijay H. Shah
Journal: Clinical and Molecular Hepatology (2015)

Alcoholic liver disease continues to be a significant cause of liver-related morbidity and mortality throughout the world. A number of diagnostic and prognostic models have been developed in the management of this condition, although specific roles for liver biopsy still remain particularly in the setting of alcoholic hepatitis. Despite a large number of recent treatment trials, the ideal pharmacotherapy approach remains undefined. Most essential is the supportive care and focus on abstinence and nutrition. Owing in part to a great deal of attention from governmental funding sources, a number of new treatment approaches are undergoing rigorous evaluation, hopefully providing future treatment options in this very severe condition. Keywords: Liver transplantation; Alcoholic hepatitis; Corticosteroids; Alcohol
Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas.
Authors: J P Marolleau, P Brice, P Morel, C Gisselbrecht
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.3.590 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8445439 Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas. J P MarolleauxJ P MarolleauSearch for articles by this author , P BricexP BriceSearch for articles by this author , P MorelxP MorelSearch for articles by this author , C GisselbrechtxC GisselbrechtSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.3.590 PDF "Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas.." Journal of Clinical Oncology, 11(3), pp. 590–591© 1993 by American Society of Clinical Oncology
Non small cell lung cancer: Do delays in diagnosis and treatment affect outcome
Authors: S. Reganti, R. M. Eisner, C. Braden, M. St. Julien, B. P. Schmitt, R. A. Durazo-Arvizu, N. Bhoopalam
Journal: Journal of Clinical Oncology (2008)

17559 Background: Delay in management of patients with non-small cell lung cancer (NSCLC) may reduce survival and quality of life. However, the minimal acceptable time delay from suspicion to treatment and factors affecting delay has not been determined. Methods: All patients with NSCLC between February 1999 and December 2005 at the Hines VA were identified and specific key dates during each patient's management course were recorded. The outcome events were death and type of intervention: definitive surgery or palliation. A retrospective cohort analysis was performed. Given a difference in expected survival based upon the disease stage we stratified patients into two groups: one group composed of patients with stage I/II disease and the other group with stage III/IV disease. Within each stratum we conducted univariate and multivariate analysis by determining the relative risk for the chosen outcome based upon the presence or absence of several potential predictors of outcome: age, race, co-morbidities (Charleson Index), presence or absence of a primary care provider and substance abuse. Results: The relative risk of death with stage I/II disease diagnosed ≤ 30 days compared to > 30 days was 0.75 (95% CI: 0.40 -1.46) and was 1.72 (95% CI: 1.28–2.31) for those with stage III/IV. The Charleson index (1–2) was associated with reduced survival (RR=1.52; 95% CI: 1.03–2.27). Lack of a primary care physician was associated with worse survival (RR=1.55; 95% CI: 1.09–1.58). Conclusions: Timely diagnosis in patients with late stage disease, patient morbidity and lack of a primary care physician was associated with worse survival. No significant financial relationships to disclose.